SELLAS Life Sciences Group Inc sell mixitrader
Start price
12.12.20
/
50%
€6.60
Target price
12.12.21
€3.00
Performance (%)
63.18%
End price
26.06.21
€10.77
Summary
This prediction ended on 26.06.21 with a price of €10.77. The price for SELLAS Life Sciences Group Inc massively increased, which is bad news for the SELL prediction by mixitrader. mixitrader has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 13.789% | 13.789% | 646.324% | 581.208% |
| iShares Core DAX® | 1,84 % | 1,39 % | 8,65 % | 62,63 % |
| iShares Nasdaq 100 | 4,66 % | -1,80 % | 27,82 % | 85,63 % |
| iShares Nikkei 225® | 3,96 % | -5,22 % | 51,81 % | 76,25 % |
| iShares S&P 500 | 3,70 % | 1,58 % | 24,09 % | 69,87 % |